Fig. 1. Effects of NL101 on the proliferation of myeloid cancer cells in vitro and in vivo. (a) The time- and dose-dependent effects of NL101 on cell proliferation in myelodysplastic syndrome (MDS) cell lines (MUTZ-1 and SKM-1) and acute myeloid leukemia (AML) cell lines (MOLM-13 and KG-1a) were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. (b) The half maximal inhibitory concentration (IC50) of NL101 in primary leukemia cells. (c) The timeline indicating the tumor injection and treatment schedule (top) and antitumor potency of NL101 in AML xenografts (bottom). (d, e) Western blot analysis of poly-(ADP-ribose) polymerase-1 (PARP-1), cleaved caspase-3, and phosphorylated γ-H2A.X in cell lines exposed to NL101 for 24 h. (f) Western blot analysis of cleaved PARP-1 in AML xenografts. Data (a, c) are expressed as mean±standard deviation (SD) (n=3). NSG: NOD-SCID-gamma; GAPDH: glyceraldehyde-3-phosphate dehydrogenase.
